eMedicine Specialties > Ophthalmology > Refractive Disorders

Myopia, PRK

Author: Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES
Contributor Information and Disclosures

Updated: Apr 18, 2006

Introduction

Photorefractive keratectomy (PRK) consists of the application of energy of the ultraviolet range generated by an argon fluoride (ArF) excimer laser to the anterior corneal stroma to change its curvature and, thus, to correct a refractive error. The physical process of remodeling the corneal stroma by ultraviolet (193 nm wavelength) high-energy photons is known as photoablation.

History of the Procedure

During the 1980s, several applications of the 193-nm ArF excimer laser were investigated, including its use on human corneas for the correction of refractive errors. In 1988, Munnerlyn, Kroons, and Marshall reported an algorithm relating diameter and depth of the ablation to the required dioptric change.

McDonald performed the first excimer PRK for the correction of myopia on a normally sighted human eye in the United States. That same year, the Food and Drug Administration (FDA) organized a 3-phase trial, the PRK study (which ended in 1996), to demonstrate the safety, predictability, and stability of PRK for the treatment of myopia. At the end of this trial, 2 ophthalmic companies, VISX and Summit, were allowed to manufacture excimer lasers for widespread use in the United States. Since then, Nidek also has obtained approval for the manufacture of excimer lasers in the United States, and several hundred thousand patients have undergone this procedure throughout the world. The first excimer lasers used to perform PRK in the late 1980s have been improved significantly in terms of size, efficiency, and accuracy.

Problem

Several epidemiological studies, including the Beaver Dam population-based survey taken in the United States, show a prevalence of myopia greater than 0.5 diopters (D), ranging from 43.0% in people aged 43-54 years to 14.4% in individuals older than 75 years.

Pathophysiology

The mechanism of ablation of the excimer laser appears to be photochemical in nature and is known as photochemical ablation or ablative photodecomposition. This highly localized tissue interaction is based on the fact that each photon produced by the ArF excimer laser has 6.4 eV of energy, enough to break covalent bonds.

The intramolecular bonds of exposed organic macromolecules are broken when a large number of high-energy 193-nm photons are absorbed in a short time. The resulting fragments rapidly expand and are ejected from the exposed surface at supersonic velocities. This mechanism explains why only the irradiated organic materials are affected, whereas the adjacent areas are not affected.

The return of corneal innervation up to 5 years after PRK was measured. Corneal subbasal nerve density does not recover to near preoperative densities until 2 years after PRK, as compared to 5 years after laser in situ keratomileusis (LASIK).

Indications

Clinical indications for PRK include the following:

  • Myopia (-1.0 D to -6.0 D) - Higher corrections are associated with a greater risk of corneal haze formation; therefore, LASIK is generally the preferred procedure.
  • Astigmatism (0.75 D to 3.0 D) - Higher corrections are associated with regression of the effect; therefore, LASIK is the preferred procedure.
  • Hyperopia (+1.0 D to +4.0 D) - Haze and regression of the PRK effect have made LASIK the preferred procedure for most of these patients.
  • Patients with documented evidence of a change in manifest refraction of less than or equal to 0.5 D (both cylinder and sphere components) per year for at least 1 year prior to the date of preoperative examination
  • Patients aged 18-20 years for the reduction or elimination of myopia of less than or equal to -6.0 D spherical equivalent at the corneal plane
  • Patients aged 21 years for the reduction or elimination of myopia from 0 D to -6.0 D spherical myopia at the spectacle plane with up to -3.0 D of astigmatism
  • Patients aged 21 years or older with naturally occurring hyperopia from +1.0 D to +4.0 D spherical equivalent, with no more than 1.0 D of refractive astigmatism
  • Correction of refractive errors following other ocular surgery, including cataract surgery - PRK has been performed in patients who had previous radial keratotomy (RK) surgery or penetrating keratoplasties, but, in those cases, LASIK appears to be preferable. A significant risk of corneal haze formation exists if PRK is performed on an eye with any previous corneal surgery, so LASIK is generally the procedure of choice because of its minimal haze risk.
  • PRK in corneas previously treated with LASIK
  • Treatment of anisometropic amblyopia in children

Relevant Anatomy

PRK ablation of the anterior stroma takes place after removing the epithelium, which is approximately 40-50 µm in thickness. The Bowman layer is destroyed in the process of PRK with no known deleterious consequences. A residual stromal thickness of at least 250 µm after PRK is necessary to prevent future corneal ectasia. A residual stromal thickness of 400 µm or more is preferred.

Contraindications

Contraindications include the following: collagen vascular, autoimmune, or immunodeficiency diseases; pregnancy or breastfeeding; keratoconus; medications, such as Accutane (isotretinoin) or Cordarone (amiodarone hydrochloride); and a history of keloid formation. A recent report on the outcome of PRK in African Americans, including those with a known history of dermatologic keloid formation, revealed that a history of keloid formation does not appear to have an adverse effect on the outcome. These results question whether known dermatologic keloid formation should be a contraindication to photorefractive keratectomy.

More on Myopia, PRK

Overview: Myopia, PRK
Workup: Myopia, PRK
Treatment: Myopia, PRK
Follow-up: Myopia, PRK
References

References

  1. Dausch D, Smecka Z, Klein R, et al. Excimer laser photorefractive keratectomy for hyperopia. J Cataract Refract Surg. Mar 1997;23(2):169-76. [Medline].

  2. Erie JC, McLaren JW, Hodge DO. Recovery of corneal subbasal nerve density after PRK and LASIK. Am J Ophthalmol. Dec 2005;140(6):1059-1064. [Medline].

  3. Gambato C, Ghirlando A, Moretto E. Mitomycin C modulation of corneal wound healing after photorefractive keratectomy in highly myopic eyes. Ophthalmology. Feb 2005;112(2):208-18; discussion 219. [Medline].

  4. Krueger RR, Trokel SL. Quantitation of corneal ablation by ultraviolet laser light. Arch Ophthalmol. Nov 1985;103(11):1741-2. [Medline].

  5. McDonald MB, Kaufman HE, Frantz JM, et al. Excimer laser ablation in a human eye. Case report. Arch Ophthalmol. May 1989;107(5):641-2. [Medline].

  6. Munnerlyn CR, Koons SJ, Marshall J. Photorefractive keratectomy: a technique for laser refractive surgery. J Cataract Refract Surg. Jan 1988;14(1):46-52. [Medline].

  7. O'Brart DP, Patsoura E, Jaycock P. Excimer laser photorefractive keratectomy for hyperopia: 7.5-year follow-up. J Cataract Refract Surg. Jun 2005;31(6):1104-13. [Medline].

  8. Paysse EA, Coats DK, Hussein MA. Long-term outcomes of photorefractive keratectomy for anisometropic amblyopia in children. Ophthalmology. Feb 2006;113(2):169-76. [Medline].

  9. Rajan MS, Jaycock P, O'Brart D. A long-term study of photorefractive keratectomy; 12-year follow-up. Ophthalmology. Oct 2004;111(10):1813-24. [Medline].

  10. Seiler T, Wollensak J. Myopic photorefractive keratectomy with the excimer laser. One-year follow-up. Ophthalmology. Aug 1991;98(8):1156-63. [Medline].

  11. Shaikh NM, Wee CE, Kaufman SC. The safety and efficacy of photorefractive keratectomy after laser in situ keratomileusis. J Refract Surg. Jul-Aug 2005;21(4):353-8. [Medline].

  12. Taboada J, Archibald CJ. An extreme sensitivity in the corneal epithelium to far UV ArF excimer laser pulses. Proceedings of the Aerospace Medical Association. San Antonio;1981.

  13. Tanzer DJ, Isfahani A, Schallhorn SC. Photorefractive keratectomy in African Americans including those with known dermatologic keloid formation. Am J Ophthalmol. Nov 1998;126(5):625-9. [Medline].

  14. Taylor HR, Guest CS, Kelly P, Alpins NA. Comparison of excimer laser treatment of astigmatism and myopia. The Excimer Laser and Research Group. Arch Ophthalmol. Dec 1993;111(12):1621-6. [Medline].

  15. Uozato H, Guyton DL. Centering corneal surgical procedures. Am J Ophthalmol. Mar 15 1987;103(3 Pt 1):264-75. [Medline].

  16. Wang Q, Klein BE, Klein R, Moss SE. Refractive status in the Beaver Dam Eye Study. Invest Ophthalmol Vis Sci. Dec 1994;35(13):4344-7. [Medline].

Further Reading

Keywords

photorefractive keratectomy, shortsighted, vision loss, visual deficit, laser surgery

Contributor Information and Disclosures

Author

Fernando H Murillo-Lopez, MD, Senior Surgeon, Unidad Privada de Oftalmologia CEMES
Fernando H Murillo-Lopez, MD is a member of the following medical societies: American Academy of Ophthalmology
Disclosure: Nothing to disclose.

Medical Editor

Daniel S Durrie, MD, Director, Department of Ophthalmology, Division of Refractive Surgery, University of Kansas Medical Center
Daniel S Durrie, MD is a member of the following medical societies: American Academy of Ophthalmology and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Managing Editor

Louis E Probst, MD, Medical Director of Refractive Surgery, Chicago, Madison, Milwaukee, and Windsor Centers, TLC the Laser Eye Centers
Louis E Probst, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Cataract and Refractive Surgery, and International Society of Refractive Surgery
Disclosure: Nothing to disclose.

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.